This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Visual Feedback Therapy for Treating Individuals With Hemiparesis Following Stroke

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Steve Jax, Albert Einstein Healthcare Network
ClinicalTrials.gov Identifier:
NCT01662960
First received: August 8, 2012
Last updated: April 3, 2017
Last verified: April 2017
August 8, 2012
April 3, 2017
September 7, 2012
February 27, 2017   (Final data collection date for primary outcome measure)
  • Fugl-Meyer [ Time Frame: 1 month ]
    This test measures impairment-level ability to move the arm.
  • Action Research Arm Test [ Time Frame: 1 month ]
    The test measures the ability and speed to completed simulated everyday tasks with the arm.
  • Rivermead Assessment of Somatosensory Performance [ Time Frame: 1 month ]
    This test measures the integrity of sensory perception of the arm.
  • Virtual-reality assessment of navigation [ Time Frame: 1 month ]
    This test measures the ability to detect attention problems in a simulated navigation test.
Same as current
Complete list of historical versions of study NCT01662960 on ClinicalTrials.gov Archive Site
  • Stroke Impact Scale [ Time Frame: 1 month ]
    This test measure the self-reported ability to complete everyday tasks with the arm.
  • Wolf motor function test [ Time Frame: 1 months ]
    The test measures the ability and speed to completed simulated everyday tasks with the arm.
Same as current
Not Provided
Not Provided
 
Visual Feedback Therapy for Treating Individuals With Hemiparesis Following Stroke
Visual Feedback Therapy for Treating Individuals With Hemiparesis Following Stroke
The purpose of the study is to determine whether an existing treatment for problems that participants have with making movements after a stroke can be performed at home.
This study will compare two forms of home-based treatment for post-stroke problems making movements with the arms and hands. After initial pre-treatment assessments, participants will complete 4 weeks of treatment, with assessments after each week of treatment and 3 months after the completion of treatment.
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Care Provider, Outcomes Assessor
Primary Purpose: Treatment
  • Hemiparesis
  • Stroke
  • Behavioral: Visual feedback therapy #1
    A home based therapy involving modification of visual feedback.
  • Behavioral: Visual feedback therapy #2
    A home based therapy involving modification of visual feedback.
  • Experimental: Visual feedback therapy #1
    In both forms of visual feedback therapy, participants will practice making movements at home without full visual feedback of their low-functioning arm.
    Intervention: Behavioral: Visual feedback therapy #1
  • Active Comparator: Visual feedback therapy #2
    In both forms of visual feedback therapy, participants will practice making movements at home without full visual feedback of their low-functioning arm.
    Intervention: Behavioral: Visual feedback therapy #2
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
72
February 27, 2017
February 27, 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • 6 months or more post-stroke
  • upper extremity Fugl-Meyer score between 10 and 50
  • no longer participating in upper-extremity physical or occupational therapy
  • sufficient comprehension ability to understand instructions

Exclusion Criteria:

  • previous head trauma, psychiatric illness or chronic exposure to medications that might be expected to have lasting consequences for the central nervous system (e.g., haloperidol, dopaminergics)
  • dementia
Sexes Eligible for Study: All
40 Years to 80 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01662960
HN 4404
NIH R01 HD068565 ( Other Identifier: Einstein Healthcare Network )
No
Not Provided
Not Provided
Steve Jax, Albert Einstein Healthcare Network
Albert Einstein Healthcare Network
Not Provided
Principal Investigator: Steven Jax, Ph. D. Albert Einstein Healthcare Network
Albert Einstein Healthcare Network
April 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP